Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.31
+1.50 (7.57%)
At close: Jun 26, 2026, 4:00 PM EDT
21.25
-0.06 (-0.28%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Syndax Pharmaceuticals Employees
Syndax Pharmaceuticals had 298 employees as of December 31, 2025. The number of employees increased by 28 or 10.37% compared to the previous year.
Employees
298
Change (1Y)
28
Growth (1Y)
10.37%
Revenue / Employee
$728,772
Profits / Employee
-$816,272
Market Cap
1.89B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| UroGen Pharma | 298 |
| Zymeworks | 243 |
| Capricor Therapeutics | 231 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
SNDX News
- 14 days ago - Syndax price target lowered to $31 from $34 at Guggenheim - TheFly
- 15 days ago - Syndax presents data from SAVE trial at EHA - TheFly
- 15 days ago - Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - GlobeNewsWire
- 15 days ago - Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology - GlobeNewsWire
- 18 days ago - Syndax Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 22 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Syndax Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 22 days ago - Syndax Pharmaceuticals Proxy statement: Proxy filing - Filings